U.S. markets open in 7 hours
  • S&P Futures

    4,129.50
    +1.75 (+0.04%)
     
  • Dow Futures

    33,705.00
    -4.00 (-0.01%)
     
  • Nasdaq Futures

    13,749.00
    -1.25 (-0.01%)
     
  • Russell 2000 Futures

    2,238.60
    +10.30 (+0.46%)
     
  • Crude Oil

    61.70
    +0.27 (+0.44%)
     
  • Gold

    1,785.90
    +3.90 (+0.22%)
     
  • Silver

    26.17
    -0.01 (-0.04%)
     
  • EUR/USD

    1.2029
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.5540
    0.0000 (0.00%)
     
  • Vix

    18.71
    +1.21 (+6.91%)
     
  • GBP/USD

    1.3857
    +0.0014 (+0.10%)
     
  • USD/JPY

    107.9500
    -0.0100 (-0.01%)
     
  • BTC-USD

    48,780.43
    -5,422.89 (-10.00%)
     
  • CMC Crypto 200

    1,102.29
    -140.76 (-11.32%)
     
  • FTSE 100

    6,938.24
    +42.95 (+0.62%)
     
  • Nikkei 225

    29,020.63
    -167.54 (-0.57%)
     

ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming H.C. Wainwright Virtual Global Life Sciences Conference. The presentation will be available on-demand on March 9, 2021 at 7:00 a.m. ET.

A webcast of the presentation will be accessible through the Investors and Media section of the Company's website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now."

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005776/en/

Contacts

INVESTOR RELATIONS AND MEDIA
ImmunoGen
Courtney O’Konek
781-895-0600
courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com